SHARE

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has today made public the findings it obtained from the Extension Period of the Phase 3 SOLUTION, non-inferiority clinical study in cystic fibrosis among patients struggling with exocrine pancreatic insufficiency .

According to the company’s insiders, that particular extension period had been put in place to serve the need of establishing the long terms effects of Pancreaze and Sollpura through carrying out an observational analysis pertaining the long-term effects.

Anthera’s Chief Medical Officer, William Shanahan is happy about the progress the company has been making lately towards creating top solutions to help patients globally. He expressed his great joy in the fact that the company was overseeing immense success in terms of the continued tolerability as well as maintenance of height and weight in among the various patients diagnosed with Sollpura treated cystic fibrosis patients with EPI during the extension duration and just to make it a little more clearer, increase in height and weight among patients less than 17 years of age.

The changing times in the world we are living in today are coming with new challenges every dawn in terms of developing complications. They are some of these complications that are forcing the research institutions to fold their sleeves in an effort to try and come up with better treatment options to help save the lives the world is loosing as a result of the complications.

Anthera Pharmaceuticals Inc is one of the high end companies that have been doing all within their means to try and develop top solutions to help patients in a great fashion. The company’s top executive added to say that indeed the 20-Week data went quite a long way towards proving the point that indeed Sollpura had whatever it took to provide patients with some alternative to what has already been there- the porcine-based pancreatic enzyme replacement therapies.

It was quite clear from the study that indeed Pancreaze and Sollpura were well tolerated which is indeed new hope for the rest of the patients wherever they may be around the globe. According to some top officials, the company is at the moment laying down strategies that will see the company initiate the Phase 3 trial in a short while.

SHARE
Previous articleOracle Corporation (NYSE:ORCL) Announces Konzum’s Move To Deploy Its Top Optimization Solutions
Next articleExtreme Networks, Inc (NASDAQ:EXTR) Purchases Broadcom Ltd (NASDAQ:AVGO)’s Data Center Networking, Sources Say
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.

LEAVE A REPLY